Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results

The partnership’s aim is to identify predictive imaging biomarkers of patient response to a specific drug-candidate, using Imaging Lab’s unique AI capabilities. The company is a Top 10 global oncology pharmaceutical company.

Median Technologies reports its business indicators for the first half of 2024, provide an update on recent successful business achievements.

Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.